News Releases

Keyword Search

Sep-01-2021
Oncternal Therapeutics Rounds Out Leadership Team with Appointment of Steven Hamburger, Ph.D. as Senior Vice President, Regulatory Affairs and Quality Assurance
Aug-05-2021
Oncternal Provides Business Update and Announces Second Quarter 2021 Financial Results
Aug-02-2021
Oncternal Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Aug-02-2021
Oncternal Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Jul-29-2021
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results
Jul-01-2021
Oncternal Therapeutics Appoints Pablo Urbaneja as Sr. Vice President, Corporate Development
Jun-01-2021
Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
May-26-2021
Oncternal Therapeutics to Participate in Jefferies Virtual Healthcare Conference
May-19-2021
Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021
May-19-2021
Oncternal Therapeutics Presents Updated Interim Data for Cirmtuzumab in Combination with Ibrutinib at ASCO 2021